Expression of immunohistochemical markers (pcna, ki-67,486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors

Urologia Internationalis

Volumn 59, Issue 2, 1997, Pages 88-94

  Vorreuther, R ^a   Hake, R ^a   Borchmann, P ^a   Lukowsky, S ^a   Thiele, J ^a   Engelmann, U ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Immunohistochemical markers; Recurrence rate; Superficial bladder tumors

Indexed keywords

ANTIBODY; CYCLINE; KI 67 ANTIGEN; MARKER; PARAFFIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA;

EID: 0030831582     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000283032     Document Type: Article

References (23)

1. Anderstrom C, Johanson S, Nilson S: The significance of lamina propria invasion in the prognosis of patients with bladder tumours, J Urol 1980;124:23-26.
2. Greene LF, Hanash KA, Farrow GM: Benign papilloma or papillary carcinoma of the bladder? J Urol 1973;110:205-207.
3. Lutzeyer W, Riibben H, Dahm H: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases, J Urol 1982; 127:250-252.
4. Mulder AH, van Hootegem JCSP, Sylvester R, Ten Kate FJW, Kurth KH, Ooms ECM, van der Kwast TH: Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67), J Pathol 1992;166:37-43.
5. Mellon K, Neal DE, Robinson MC, Marsh C, Wright C: Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67, Br, J Urol 1990;66:281-285.
6. Mostofi FK: International Histological Classification of Tumours, Histological Typing of Urinary Bladder Tumours, Geneva, WHO, 1973.
7. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections, J Pathol 1992;168:357-363.
8. Cordell JL, Falini B, Erber WN, Ghosh A, Abduiaziz Z, MacDonald S, Pulford KAF, Stein H, Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes), Histochem Cytochem 1984;32:219-229.
9. Lipponen PK, Eskelinen MJ: Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value, Br J Cancer 1992;66:171-176.
10. Lipponen PK: Interrelationship between expression of p53, proliferating cell nuclear antigen and C-erbb-2 in bladder cancer, Pathobiol 1993;61:178-182.
11. Bravo R, Frank R, Blindell PA, Macdonald-Bravo H: Caclin/PCNA is the auxiliary' protein to DNA polymcrasc-dclta, Nature 1987;326: 515-520.
12. Jaskulski D, Deriel JK, Merchcr WE, Calabret-ta B, Baserga R: Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA Cyclin, Science 1988;240:1544-1546.
13. Tsujihashi H, Nakanishi A, Matsuda H, Ueji-ma S, Kurita T: Cell proliferation of human bladder tumors determined by BRDURD and Ki-67 immunostaining, J Urol 1991;145:846-849.
14. Jenkins JR, Sturzbacher HW: The p53 oncogene; in Reddy EP (ed): The Oncogene Handbook, Amsterdam, Elsevier, 1988, pp 403-423.
15. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP: Human p53 gene is localised to short arm of chromosome 17, Nature 1986;319:783-784.
16. Sidransky D, Eschenbach A, Tsai Y, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton S, Frost P, Vogclstein B: Identification of p53 gene mutations in bladder cancers and urine samples, Science 1991;252:706-709.
17. Huland E, Huland H, Schneider AW: Quantitative immunocytology in the management of patients with superficial bladder carcinoma, I, A marker to identify patients who do not require prophylaxis, J Urol 1990; 144:637-640.
18. Klan R, Huland E, Baisch H, Huland H: Sensitivity of urinary quantitative immunocytology w'ith monoclonal antibody 486p3/12 in 241 unselected patients with bladder carcinoma, J Urol 1991;145:495-497.
19. Barnes R, Hadley H, Dirck A, Johnston O, Dexter J: Changes in grade and stage of recurrent bladder tumors, J Urol 1977; 118:177-178.
20. Gilbert HA, Logan JL, Kagan AR, Friedman HA, Cove JK, Fox M, Muldoon TM, Lonni YW, Rowe JH, Cooper JF, Nussbaum H, Chan P, Rao A, Starr A: The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading, J Urol 1978; 119:488-492.
21. Althausen AF, Prout GR, Daly JJ: Non-inva-sive papillary carcinoma of the bladder associated with carcinoma in situ, J Urol 1976; 116: 575-580.
22. Schade ROK, Swinney J: The association of urothelial atypism with neoplasia: Its importance in treatment and prognosis, J Urol 1973; 109:619-622.
23. Wynford-Thomas D: p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 1992;166:329-330.